Skip to main content
PMC home page
Protein & Cell logoLink to Protein & Cell
. 2010 Apr 1;1(4):342–354. doi: 10.1007/s13238-010-0054-6

Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines

Shibo Jiang 1,2,✉, Runming Li 2, Lanying Du 1, Shuwen Liu 2,✉
PMCID: PMC4728157  PMID: 21203946

Abstract

Seasonal influenza epidemics and influenza pandemics caused by influenza A virus (IAV) has resulted in millions of deaths in the world. The development of anti-IAV vaccines and therapeutics is urgently needed for prevention and treatment of IAV infection and for controlling future influenza pandemics. Hemagglutinin (HA) of IAV plays a critical role in viral binding, fusion and entry, and contains the major neutralizing epitopes. Therefore, HA is an attractive target for developing anti-IAV drugs and vaccines. Here we have reviewed the recent progress in study of conformational changes of HA during viral fusion process and development of HA-based antiviral therapeutics and vaccines.

Keywords: influenza A virus, hemagglutinin, viral entry, antiviral drugs, vaccines

Contributor Information

Shibo Jiang, Email: sjiang@nybloodcenter.org.

Shuwen Liu, Email: liusw@smu.edu.cn.

References

  1. Amorij J.P., Meulenaar J., Hinrichs W.L., Stegmann T., Huckriede A., Coenen F., Frijlink H.W. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying. Vaccine. 2007;25:6447–6457. doi: 10.1016/j.vaccine.2007.06.054. [DOI] [PubMed] [Google Scholar]
  2. Barefoot B.E., Athearn K., Sample C.J., Ramsburg E.A. Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge. Vaccine. 2009;28:79–89. doi: 10.1016/j.vaccine.2009.09.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., Truitt D.M., Sumida S.M., Kishko M.G., Arthur J. C., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004;172:6290–6297. doi: 10.4049/jimmunol.172.10.6290. [DOI] [PubMed] [Google Scholar]
  4. Beppu Y., Imamura Y., Tashiro M., Towatari T., Ariga H., Kido H. Human mucus protease inhibitor in airway fluids is a potential defensive compound against infection with influenza A and Sendai viruses. J Biochem. 1997;121:309–316. doi: 10.1093/oxfordjournals.jbchem.a021588. [DOI] [PubMed] [Google Scholar]
  5. Biesova Z., Miller M.A., Schneerson R., Shiloach J., Green K.Y., Robbins J.B., Keith J.M. Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine. 2009;27:6234–6238. doi: 10.1016/j.vaccine.2009.07.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bizebard T., Gigant B., Rigolet P., Rasmussen B., Diat O., Bösecke P., Wharton S.A., Skehel J.J., Knossow M. Structure of influenza virus haemagglutinin complexed with a neutralizing antibody. Nature. 1995;376:92–94. doi: 10.1038/376092a0. [DOI] [PubMed] [Google Scholar]
  7. Bodian D.L., Yamasaki R.B., Buswell R.L., Stearns J.F., White J. M., Kuntz I.D. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry. 1993;32:2967–2978. doi: 10.1021/bi00063a007. [DOI] [PubMed] [Google Scholar]
  8. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J. D., Cole K.S., Kumar N.M., Pushko P., Smith G., Tumpey T.M., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008;3:e1501. doi: 10.1371/journal.pone.0001501. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bullough P.A., Hughson F.M., Skehel J.J., Wiley D.C. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature. 1994;371:37–43. doi: 10.1038/371037a0. [DOI] [PubMed] [Google Scholar]
  10. Carr C.M., Kim P.S. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell. 1993;73:823–832. doi: 10.1016/0092-8674(93)90260-W. [DOI] [PubMed] [Google Scholar]
  11. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997;89:263–273. doi: 10.1016/S0092-8674(00)80205-6. [DOI] [PubMed] [Google Scholar]
  12. Chan D.C., Chutkowski C.T., Kim P.S. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A. 1998;95:15613–15617. doi: 10.1073/pnas.95.26.15613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Chen Q., Kuang H., Wang H., Fang F., Yang Z., Zhang Z., Zhang X., Chen Z. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes. 2009;38:30–38. doi: 10.1007/s11262-008-0305-2. [DOI] [PubMed] [Google Scholar]
  14. Chen Y., Qin K., Wu W.L., Li G., Zhang J., Du H., Ng M.H., Shih J.W., Peiris J.S., Guan Y., et al. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis. 2009;199:49–58. doi: 10.1086/594374. [DOI] [PubMed] [Google Scholar]
  15. Delano W.L. The PyMOL molecular graphics system. 400, Oyster Point Blvd., Suite 213, South San Francisco, CA 94080-1918 USA: DeLano Scientific LLC.; 2005. [Google Scholar]
  16. DiNapoli J.M., Nayak B., Yang L., Finneyfrock B.W., Cook A., Andersen H., Torres-Velez F., Murphy B.R., Samal S.K., Collins P.L., et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol. 2010;84:1489–1503. doi: 10.1128/JVI.01946-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Du L., He Y., Jiang S., Zheng B.J. Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc) 2008;44:63–73. doi: 10.1358/dot.2008.44.1.1131830. [DOI] [PubMed] [Google Scholar]
  18. Du L., Zhou Y., Jiang S. Research and development of universal influenza vaccines. Microbes Infect. 2010;12:280–286. doi: 10.1016/j.micinf.2010.01.001. [DOI] [PubMed] [Google Scholar]
  19. Durrer P., Galli C., Hoenke S., Corti C., Glück R., Vorherr T., Brunner J. H +-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region. J Biol Chem. 1996;271:13417–13421. doi: 10.1074/jbc.271.23.13417. [DOI] [PubMed] [Google Scholar]
  20. Dwyer J.J., Wilson K.L., Davison D.K., Freel S.A., Seedorff J.E., Wring S.A., Tvermoes N.A., Matthews T.J., Greenberg M.L., Delmedico M.K. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A. 2007;104:12772–12777. doi: 10.1073/pnas.0701478104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., Goudsmit J., Wilson I.A. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324:246–251. doi: 10.1126/science.1171491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ellebedy A.H., Webby R.J. Influenza vaccines. Vaccine. 2009;27:D65–D68. doi: 10.1016/j.vaccine.2009.08.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Fleury D., Wharton S.A., Skehel J.J., Knossow M., Bizebard T. Antigen distortion allows influenza virus to escape neutralization. Nat Struct Biol. 1998;5:119–123. doi: 10.1038/nsb0298-119. [DOI] [PubMed] [Google Scholar]
  24. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., Robbins P.D., Swayne D.E., Donis R.O., Katz J. M., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol. 2006;80:1959–1964. doi: 10.1128/JVI.80.4.1959-1964.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., Sessions W.M., Xu X., Skepner E., Deyde V., et al. Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science. 2009;325:197–201. doi: 10.1126/science.1176225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Harrison S.C. Viral membrane fusion. Nat Struct Mol Biol. 2008;15:690–698. doi: 10.1038/nsmb.1456. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Haynes J.R. Influenza virus-like particle vaccines. Expert Rev Vaccines. 2009;8:435–445. doi: 10.1586/erv.09.8. [DOI] [PubMed] [Google Scholar]
  28. Hoffman L.R., Kuntz I.D., White J.M. Structure-based identification of an inducer of the low-pH conformational change in the influenza virus hemagglutinin: irreversible inhibition of infectivity. J Virol. 1997;71:8808–8820. doi: 10.1128/jvi.71.11.8808-8820.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Hosoya M., Matsuyama S., Baba M., Suzuki H., Shigeta S. Effects of protease inhibitors on replication of various myxoviruses. Antimicrob Agents Chemother. 1992;36:1432–1436. doi: 10.1128/AAC.36.7.1432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Itoh Y., Shinya K., Kiso M., Watanabe T., Sakoda Y., Hatta M., Muramoto Y., Tamura D., Sakai-Tagawa Y., Noda T., et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460:1021–1025. doi: 10.1038/nature08260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ji H., Shu W., Burling T., Jiang S., Lu M. Inhibition of HIV-1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol. 1999;73:8578–8586. doi: 10.1128/jvi.73.10.8578-8586.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Jiang S., Lin K., Strick N., Neurath A.R. HIV-1 inhibition by a peptide. Nature. 1993;365:113. doi: 10.1038/365113a0. [DOI] [PubMed] [Google Scholar]
  33. Jones S., Evans K., McElwaine-Johnn H., Sharpe M., Oxford J., Lambkin-Williams R., Mant T., Nolan A., Zambon M., Ellis J., et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine. 2009;27:2506–2512. doi: 10.1016/j.vaccine.2009.02.061. [DOI] [PubMed] [Google Scholar]
  34. Kang S.M., Yoo D.G., Lipatov A.S., Song J.M., Davis C.T., Quan F. S., Chen L.M., Donis R.O., Compans R.W., Broliden K. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE. 2009;4:e4667. doi: 10.1371/journal.pone.0004667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Kido H., Yokogoshi Y., Sakai K., Tashiro M., Kishino Y., Fukutomi A., Katunuma N. Isolation and characterization of a novel trypsin-like protease found in rat bronchiolar epithelial Clara cells. A possible activator of the viral fusion glycoprotein. J Biol Chem. 1992;267:13573–13579. [PubMed] [Google Scholar]
  36. Kido H., Sakai K., Kishino Y., Tashiro M. Pulmonary surfactant is a potential endogenous inhibitor of proteolytic activation of Sendai virus and influenza A virus. FEBS Lett. 1993;322:115–119. doi: 10.1016/0014-5793(93)81549-F. [DOI] [PubMed] [Google Scholar]
  37. Kido H., Okumura Y., Yamada H., Le T.Q., Yano M. Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents. Curr Pharm Des. 2007;13:405–414. doi: 10.2174/138161207780162971. [DOI] [PubMed] [Google Scholar]
  38. Kielian M., Rey F.A. Virus membrane-fusion proteins: more than one way to make a hairpin. Nat Rev Microbiol. 2006;4:67–76. doi: 10.1038/nrmicro1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Kilby J.M., Eron J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med. 2003;348:2228–2238. doi: 10.1056/NEJMra022812. [DOI] [PubMed] [Google Scholar]
  40. King J.C., Jr, Cox M.M., Reisinger K., Hedrick J., Graham I., Patriarca P. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirusexpressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6–59 months. Vaccine. 2009;27:6589–6594. doi: 10.1016/j.vaccine.2009.08.032. [DOI] [PubMed] [Google Scholar]
  41. Kreijtz J.H., Suezer Y., de Mutsert G., van den Brand J.M., van Amerongen G., Schnierle B.S., Kuiken T., Fouchier R.A., Löwer J., Osterhaus A.D., et al. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine. 2009;27:6296–6299. doi: 10.1016/j.vaccine.2009.03.020. [DOI] [PubMed] [Google Scholar]
  42. Kreijtz J.H., Suezer Y., de Mutsert G., van den Brand J.M., van Amerongen G., Schnierle B.S., Kuiken T., Fouchier R.A., Löwer J., Osterhaus A.D., et al. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis. 2009;199:405–413. doi: 10.1086/595984. [DOI] [PubMed] [Google Scholar]
  43. Kubota-Koketsu R., Mizuta H., Oshita M., Ideno S., Yunoki M., Kuhara M., Yamamoto N., Okuno Y., Ikuta K. Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors. Biochem Biophys Res Commun. 2009;387:180–185. doi: 10.1016/j.bbrc.2009.06.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Lambert D.M., Barney S., Lambert A.L., Guthrie K., Medinas R., Davis D.E., Bucy T., Erickson J., Merutka G., Petteway S.R., Jr. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A. 1996;93:2186–2191. doi: 10.1073/pnas.93.5.2186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Lasaro M.O., Ertl H.C. New insights on adenovirus as vaccine vectors. Mol Ther. 2009;17:1333–1339. doi: 10.1038/mt.2009.130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Le T.Q., Kawachi M., Yamada H., Shiota M., Okumura Y., Kido H. Identification of trypsin I as a candidate for influenza A virus and Sendai virus envelope glycoprotein processing protease in rat brain. Biol Chem. 2006;387:467–475. doi: 10.1515/BC.2006.062. [DOI] [PubMed] [Google Scholar]
  47. Le Q.M., Wertheim H.F., Tran N.D., van Doorn H.R., Nguyen T.H., Horby P., the Vietnam H1N1 Investigation Team A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med. 2010;362:86–87. doi: 10.1056/NEJMc0910448. [DOI] [PubMed] [Google Scholar]
  48. Li F.C., Choi B.C., Sly T., Pak A.W. Finding the real case-fatality rate of H5N1 avian influenza. J Epidemiol Community Health. 2008;62:555–559. doi: 10.1136/jech.2007.064030. [DOI] [PubMed] [Google Scholar]
  49. Liu S., Xiao G., Chen Y., He Y., Niu J., Escalante C.R., Xiong H., Farmar J., Debnath A.K., Tien P., et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363:938–947. doi: 10.1016/S0140-6736(04)15788-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Liu S., Wu S., Jiang S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des. 2007;13:143–162. doi: 10.2174/138161207779313722. [DOI] [PubMed] [Google Scholar]
  51. Liu J., Stevens D.J., Haire L.F., Walker P.A., Coombs P.J., Russell R.J., Gamblin S.J., Skehel J.J. Structures of receptor complexes formed by hemagglutinins from the Asian Influenza pandemic of 1957. Proc Natl Acad Sci U S A. 2009;106:17175–17180. doi: 10.1073/pnas.0906849106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Lu M., Blacklow S.C., Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol. 1995;2:1075–1082. doi: 10.1038/nsb1295-1075. [DOI] [PubMed] [Google Scholar]
  53. Luo G., Colonno R., Krystal M. Characterization of a hemagglutinin-specific inhibitor of influenza A virus. Virology. 1996;226:66–76. doi: 10.1006/viro.1996.0628. [DOI] [PubMed] [Google Scholar]
  54. Luo G., Torri A., Harte W.E., Danetz S., Cianci C., Tiley L., Day S., Mullaney D., Yu K.L., Ouellet C., et al. Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. J Virol. 1997;71:4062–4070. doi: 10.1128/jvi.71.5.4062-4070.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., Klenk H.D. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A. 2004;101:4620–4624. doi: 10.1073/pnas.0308001101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Miller M.A., Viboud C., Balinska M., Simonsen L. The signature features of influenza pandemics—implications for policy. N Engl J Med. 2009;360:2595–2598. doi: 10.1056/NEJMp0903906. [DOI] [PubMed] [Google Scholar]
  57. Minagawa K., Kouzuki S., Kamigauchi T. Stachyflin and acetylstachyflin, novel anti-influenza A virus substances, produced by Stachybotrys sp. RF-7260. II. Synthesis and preliminary structure-activity relationships of stachyflin derivatives. J Antibiot (Tokyo) 2002;55:165–171. doi: 10.7164/antibiotics.55.165. [DOI] [PubMed] [Google Scholar]
  58. Mitchell D.K., Ruben F.L., Gravenstein S. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003–2004. Pediatr Infect Dis J. 2005;24:925–927. doi: 10.1097/01.inf.0000180978.66362.d9. [DOI] [PubMed] [Google Scholar]
  59. Mitrasinovic P.M. Advances in the structure-based design of the influenza A neuraminidase inhibitors. Curr Drug Targets. 2010;11:315–326. doi: 10.2174/138945010790711932. [DOI] [PubMed] [Google Scholar]
  60. Murakami M., Towatari T., Ohuchi M., Shiota M., Akao M., Okumura Y., Parry M.A., Kido H. Mini-plasmin found in the epithelial cells of bronchioles triggers infection by broad-spectrum influenza A viruses and Sendai virus. Eur J Biochem. 2001;268:2847–2855. doi: 10.1046/j.1432-1327.2001.02166.x. [DOI] [PubMed] [Google Scholar]
  61. Naeve C.W., Hinshaw V.S., Webster R.G. Mutations in the hemagglutinin receptor-binding site can change the biological properties of an influenza virus. J Virol. 1984;51:567–569. doi: 10.1128/jvi.51.2.567-569.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Ndifon W., Wingreen N.S., Levin S.A. Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proc Natl Acad Sci U S A. 2009;106:8701–8706. doi: 10.1073/pnas.0903427106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Okumura Y., Sato H., Seiki M., Kido H. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett. 1997;402:181–184. doi: 10.1016/S0014-5793(96)01523-2. [DOI] [PubMed] [Google Scholar]
  64. Okumura, Y., Takahashi, E., Yano, M., Ohuchi, M., Daidoji, T., Nakaya, T., Bottcher, E., Garten, W., Klenk, H.D., and Kido, H. (2010). Novel type II transmembrane serine proteases, MSPL and TMPRSS13, proteolytically activate membrane fusion activity of hemagglutinin of highly pathogenic avian influenza viruses and induce their multicycle replication. J Virol, 10. [DOI] [PMC free article] [PubMed]
  65. Pan, C. and Jiang, S. (2009). E14-F55 combination in M2 protein: a putative molecular determinant responsible for swine-origin influenza A virus transmission in humans. PLoS Curr Influenza RRN1044. [DOI] [PMC free article] [PubMed]
  66. Pan C., Cheung B., Tan S., Li C., Li L., Liu S., Jiang S. Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus. PLoS ONE. 2010;5:e9549. doi: 10.1371/journal.pone.0009549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Patel A., Tran K., Gray M., Li Y., Ao Z., Yao X., Kobasa D., Kobinger G.P. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine. 2009;27:3083–3089. doi: 10.1016/j.vaccine.2009.03.023. [DOI] [PubMed] [Google Scholar]
  68. Perdue M.L., García M., Senne D., Fraire M. Virulenceassociated sequence duplication at the hemagglutinin cleavage site of avian influenza viruses. Virus Res. 1997;49:173–186. doi: 10.1016/S0168-1702(97)01468-8. [DOI] [PubMed] [Google Scholar]
  69. Plotch S.J., O’Hara B., Morin J., Palant O., LaRocque J., Bloom J. D., Lang S.A.J., Jr, DiGrandi M.J., Bradley M., Nilakantan R., et al. Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin. J Virol. 1999;73:140–151. doi: 10.1128/jvi.73.1.140-151.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Prabhu N., Prabakaran M., Ho H.T., Velumani S., Qiang J., Goutama M., Kwang J. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol. 2009;83:2553–2562. doi: 10.1128/JVI.02165-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Quan F.S., Steinhauer D., Huang C., Ross T.M., Compans R.W., Kang S.M. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine. 2008;26:3352–3361. doi: 10.1016/j.vaccine.2008.03.055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Reed M.L., Bridges O.A., Seiler P., Kim J.K., Yen H.L., Salomon R., Govorkova E.A., Webster R.G., Russell C.J. The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity and transmissibility in ducks. J Virol. 2010;84:1527–1535. doi: 10.1128/JVI.02069-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Rogers G.N., Paulson J.C. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology. 1983;127:361–373. doi: 10.1016/0042-6822(83)90150-2. [DOI] [PubMed] [Google Scholar]
  74. Ruben F.L. Inactivated influenza virus vaccines in children. Clin Infect Dis. 2004;38:678–688. doi: 10.1086/382883. [DOI] [PubMed] [Google Scholar]
  75. Russell R.J., Kerry P.S., Stevens D.J., Steinhauer D.A., Martin S. R., Gamblin S.J., Skehel J.J. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008;105:17736–17741. doi: 10.1073/pnas.0807142105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Safdar A., Cox M.M. Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opin Investig Drugs. 2007;16:927–934. doi: 10.1517/13543784.16.7.927. [DOI] [PubMed] [Google Scholar]
  77. Sahini L., Tempczyk-Russell A., Agarwal R., Lau A.T.Y. Large-scale sequence analysis of hemagglutinin of influenza A virus identifies conserved regions suitable for targeting an anti-viral response. PLoS ONE. 2010;5:e9268. doi: 10.1371/journal.pone.0009268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Sasaki S., Jaimes M.C., Holmes T.H., Dekker C.L., Mahmood K., Kemble G.W., Arvin A.M., Greenberg H.B. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol. 2007;81:215–228. doi: 10.1128/JVI.01957-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Schröder E., Phillips C., Garman E., Harlos K., Crawford C. X-ray crystallographic structure of a papain-leupeptin complex. FEBS Lett. 1993;315:38–42. doi: 10.1016/0014-5793(93)81128-M. [DOI] [PubMed] [Google Scholar]
  80. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69:531–569. doi: 10.1146/annurev.biochem.69.1.531. [DOI] [PubMed] [Google Scholar]
  81. Smith G.J.D., Vijaykrishna D., Bahl J., Lycett S.J., Worobey M., Pybus O.G., Ma S.K., Cheung C.L., Raghwani J., Bhatt S., et al. Origins and evolutionary genomics of the 2009 swineorigin H1N1 influenza A epidemic. Nature. 2009;459:1122–1125. doi: 10.1038/nature08182. [DOI] [PubMed] [Google Scholar]
  82. Smith L.R., Wloch M.K., Ye M., Reyes L.R., Boutsaboualoy S., Dunne C.E., Chaplin J.A., Rusalov D., Rolland A.P., Fisher C.L., et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine. 2010;28:2565–2572. doi: 10.1016/j.vaccine.2010.01.029. [DOI] [PubMed] [Google Scholar]
  83. Staschke K.A., Hatch S.D., Tang J.C., Hornback W.J., Munroe J. E., Colacino J.M., Muesing M.A. Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid. Virology. 1998;248:264–274. doi: 10.1006/viro.1998.9273. [DOI] [PubMed] [Google Scholar]
  84. Steinhauer D.A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology. 1999;258:1–20. doi: 10.1006/viro.1999.9716. [DOI] [PubMed] [Google Scholar]
  85. Stephenson I., Nicholson K.G., Glück R., Mischler R., Newman R. W., Palache A.M., Verlander N.Q., Warburton F., Wood J.M., Zambon M.C. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet. 2003;362:1959–1966. doi: 10.1016/S0140-6736(03)15014-3. [DOI] [PubMed] [Google Scholar]
  86. Stevens J., Blixt O., Tumpey T.M., Taubenberger J.K., Paulson J. C., Wilson I.A. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science. 2006;312:404–410. doi: 10.1126/science.1124513. [DOI] [PubMed] [Google Scholar]
  87. Stieneke-Gröber A., Vey M., Angliker H., Shaw E., Thomas G., Roberts C., Klenk H.D., Garten W. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J. 1992;11:2407–2414. doi: 10.1002/j.1460-2075.1992.tb05305.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., Santelli E., Stec B., Cadwell G., Ali M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009;16:265–273. doi: 10.1038/nsmb.1566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Tashiro M., Klenk H.D., Rott R. Inhibitory effect of a protease inhibitor, leupeptin, on the development of influenza pneumonia, mediated by concomitant bacteria. J Gen Virol. 1987;68:2039–2041. doi: 10.1099/0022-1317-68-7-2039. [DOI] [PubMed] [Google Scholar]
  90. Taubenberger J.K. The origin and virulence of the 1918 “Spanish” influenza virus. Proc Am Philos Soc. 2006;150:86–112. [PMC free article] [PubMed] [Google Scholar]
  91. Tompkins S.M., Lin Y., Leser G.P., Kramer K.A., Haas D.L., Howerth E.W., Xu J., Kennett M.J., Durbin R.K., Durbin J.E., et al. Recombinant parainfluenza virus 5 (PIV5) expressing the influenza A virus hemagglutinin provides immunity in mice to influenza A virus challenge. Virology. 2007;362:139–150. doi: 10.1016/j.virol.2006.12.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006;354:1343–1351. doi: 10.1056/NEJMoa055778. [DOI] [PubMed] [Google Scholar]
  93. Walensky L.D., Kung A.L., Escher I., Malia T.J., Barbuto S., Wright R.D., Wagner G., Verdine G.L., Korsmeyer S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004;305:1466–1470. doi: 10.1126/science.1099191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Wang H., Qi Z., Guo A., Mao Q., Lu H., An X., Xia C., Li X., Debnath A.K., Wu S., et al. ADS-J1 inhibits HIV-1 entry by interacting with the gp41 pocket region and blocking the fusionactive gp41 core formation. Antimicrob Agents Chemother. 2009;53:4987–4998. doi: 10.1128/AAC.00670-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Watts G. A/H1N1 influenza virus: the basics. BMJ. 2009;339:b3046. doi: 10.1136/bmj.b3046. [DOI] [PubMed] [Google Scholar]
  96. Wei C.J., Xu L., Kong W.P., Shi W., Canis K., Stevens J., Yang Z. Y., Dell A., Haslam S.M., Wilson I.A., et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemag-glutinin proteins from avian H5N1 influenza virus. J Virol. 2008;82:6200–6208. doi: 10.1128/JVI.00187-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Weis W., Brown J.H., Cusack S., Paulson J.C., Skehel J.J., Wiley D.C. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 1988;333:426–431. doi: 10.1038/333426a0. [DOI] [PubMed] [Google Scholar]
  98. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 1997;387:426–430. doi: 10.1038/387426a0. [DOI] [PubMed] [Google Scholar]
  99. Weissenhorn W., Carfí A., Lee K.H., Skehel J.J., Wiley D.C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell. 1998;2:605–616. doi: 10.1016/S1097-2765(00)80159-8. [DOI] [PubMed] [Google Scholar]
  100. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., Matthews T.J. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994;91:9770–9774. doi: 10.1073/pnas.91.21.9770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Wilson I.A., Skehel J.J., Wiley D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature. 1981;289:366–373. doi: 10.1038/289366a0. [DOI] [PubMed] [Google Scholar]
  102. Xu Y., Gao S., Cole D.K., Zhu J., Su N., Wang H., Gao G.F., Rao Z. Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses. Biochem Biophys Res Commun. 2004;315:664–670. doi: 10.1016/j.bbrc.2004.01.115. [DOI] [PubMed] [Google Scholar]
  103. Xu Y., Lou Z., Liu Y., Pang H., Tien P., Gao G.F., Rao Z. Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem. 2004;279:49414–49419. doi: 10.1074/jbc.M408782200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Xu R., McBride R., Paulson J.C., Basler C.F., Wilson I.A. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol. 2010;84:1715–1721. doi: 10.1128/JVI.02162-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Yamashita A., Kawashita N., Kubota-Koketsu R., Inoue Y., Watanabe Y., Ibrahim M.S., Ideno S., Yunoki M., Okuno Y., Takagi T., et al. Highly conserved sequences for human neutralization epitope on hemagglutinin of influenza A viruses H3N2, H1N1 and H5N1: Implication for human monoclonal antibody recognition. Biochem Biophys Res Commun. 2010;393:614–618. doi: 10.1016/j.bbrc.2010.02.031. [DOI] [PubMed] [Google Scholar]
  106. Yoshimoto J., Kakui M., Iwasaki H., Fujiwara T., Sugimoto H., Hattori N. Identification of a novel HA conformational change inhibitor of human influenza virus. Arch Virol. 1999;144:865–878. doi: 10.1007/s007050050552. [DOI] [PubMed] [Google Scholar]
  107. Yoshimoto J., Kakui M., Iwasaki H., Sugimoto H., Fujiwara T., Hattori N. Identification of amino acids of influenza virus HA responsible for resistance to a fusion inhibitor, Stachyflin. Microbiol Immunol. 2000;44:677–685. doi: 10.1111/j.1348-0421.2000.tb02549.x. [DOI] [PubMed] [Google Scholar]
  108. Yoshimoto J., Yagi S., Ono J., Sugita K., Hattori N., Fujioka T., Fujiwara T., Sugimoto H., Hashimoto N. Development of anti-influenza drugs: II. Improvement of oral and intranasal absorption and the anti-influenza activity of stachyflin derivatives. J Pharm Pharmacol. 2000;52:1247–1255. doi: 10.1211/0022357001777225. [DOI] [PubMed] [Google Scholar]
  109. Zhang H., Zhao Q., Bhattacharya S., Waheed A.A., Tong X., Hong A., Heck S., Curreli F., Goger M., Cowburn D., et al. A cell-penetrating helical peptide as a potential HIV-1 inhibitor. J Mol Biol. 2008;378:565–580. doi: 10.1016/j.jmb.2008.02.066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Zhirnov O.P., Ovcharenko A.V., Bukrinskaya A.G. Suppression of influenza virus replication in infected mice by protease inhibitors. J Gen Virol. 1984;65:191–196. doi: 10.1099/0022-1317-65-1-191. [DOI] [PubMed] [Google Scholar]
  111. Zhu J., Xiao G., Xu Y., Yuan F., Zheng C., Liu Y., Yan H., Cole D. K., Bell J.I., Rao Z., et al. Following the rule: formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors. Biochem Biophys Res Commun. 2004;319:283–288. doi: 10.1016/j.bbrc.2004.04.141. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES